Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L E Friberg

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|January 25, 2012
Evaluation of IPPSE, an alternative method for sequential population PKPD analysisB D Lacroix, L E Friberg, M O Karlsson
CPT: Pharmacometrics & Systems Pharmacology|October 30, 2014
Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab PegolB D Lacroix, M O Karlsson, L E Friberg
The Journal of Pharmacology and Experimental Therapeutics|October 25, 2000
Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in ratsL E Friberg, A Freijs, M Sandström, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 30, 2010
Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEMK J F Petersson, L E Friberg, M O Karlsson
Clinical Pharmacology and Therapeutics|April 24, 2009
Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophreniaL E Friberg, R de Greef, T Kerbusch, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 6, 2017
A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma PatientsE Schindler, M A Amantea, M O Karlsson, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 15, 2016
PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumorE Schindler, M A Amantea, M O Karlsson, et al.
Clinical Pharmacology and Therapeutics|April 6, 2007
Pharmacokinetics of quetiapine in overdose and the effect of activated charcoalG K Isbister, L E Friberg, L P Hackett, et al.
European Journal of Clinical Pharmacology|January 11, 2001
Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC)L E Friberg, C J Brindley, M O Karlsson, et al.
Clinical Pharmacology and Therapeutics|December 26, 2008
An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatmentL E Friberg, A M Vermeulen, K J F Petersson, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Journal of Pharmacokinetics and Pharmacodynamics|January 25, 2012
Evaluation of IPPSE, an alternative method for sequential population PKPD analysisB D Lacroix, L E Friberg, M O Karlsson
CPT: Pharmacometrics & Systems Pharmacology|October 30, 2014
Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab PegolB D Lacroix, M O Karlsson, L E Friberg
The Journal of Pharmacology and Experimental Therapeutics|October 25, 2000
Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in ratsL E Friberg, A Freijs, M Sandström, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 30, 2010
Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEMK J F Petersson, L E Friberg, M O Karlsson
Clinical Pharmacology and Therapeutics|April 24, 2009
Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophreniaL E Friberg, R de Greef, T Kerbusch, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 6, 2017
A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma PatientsE Schindler, M A Amantea, M O Karlsson, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 15, 2016
PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumorE Schindler, M A Amantea, M O Karlsson, et al.
Clinical Pharmacology and Therapeutics|April 6, 2007
Pharmacokinetics of quetiapine in overdose and the effect of activated charcoalG K Isbister, L E Friberg, L P Hackett, et al.
European Journal of Clinical Pharmacology|January 11, 2001
Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC)L E Friberg, C J Brindley, M O Karlsson, et al.
Clinical Pharmacology and Therapeutics|December 26, 2008
An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatmentL E Friberg, A M Vermeulen, K J F Petersson, et al.
Pageof 4